- Market cap
- Revenue
- Net income
- Cash on hand
- Gross margin
- Net margin
- EPS
- P/E ratio
The company was founded in 2007 as Genesis Biopharma. In 2013, Lion merged with Genesis Biopharma аnd became Lion Bio Pharma, which was then rebranded to Iovance in 2017.
In 2024, the US FDA gave accelerated approval to Lifileucel, marketed under the brand name Amtagvi, the company's tumor-infiltrating lymphocyte drug for the treatment of unresectable or metastatic melanoma.
TIL monotherapy and TIL combination therapies are being investigated by Iovance in multiple clinical studies in multiple advanced solid tumor cancers such as NSCLC and sarcoma.
TIL therapy is manufactured at their 136,000–square-foot Cell Therapy Center, located in Philadelphia, PA, using proprietary good manufacturing practices (GMP).